Methods
malignancy, infection, cardiac arrest
ACUTE MYOCARDIAL INFARCTION, SKIN, RECRUITMENT, CARDIAC ARREST, CHRONIC OBSTRUCTIVE PULMONARY DISEASE, INFECTION
This was a randomized parallel controlled trial. Adult patients undergoing LT were screened for eligibility. Active status on the waiting list was the only inclusion criterion. Exclusion criteria comprised active infection, malignancy, cardiac arrest during transplantation, chronic obstructive pulmonary disease, and acute myocardial infarction. Recruitment took place between July 27, 2016, and March 2020 with follow-up for short-term outcomes completed on June 2020. The study protocol was approved by the institutional review board of the Medical University of Warsaw (KB/158/2016) and registered at Immediately after transplantation, patients were randomized by physician on duty in the department with a 1:1 allocation ratio, randomly selected blocks of 6, 8, and 10, and stratification by Child-Turcotte-Pugh class, to either 80% or 28% FiOThe primary outcome measure was the occurrence of infection in the 30-day postoperative period according to CDC definitions [The hypothesis was that provision of 80% FiOAll patients received antibiotic prophylaxis, including intravenous piperacillin/tazobactam 4.5 g every 8 h for 3 days after first transplantations and meropenem every 8 h with vancomycin 1.0 g every 12 h adjusted for serum concentration for 7 days after re-transplantations. Antifungal prophylaxis comprised fluconazole 0.4 g every 24 h for 3 and 7 days, respectively. Hair was removed with a clipper immediately before patient transfer to the operating theater. Skin was prepared with povidone-iodine solution. Standard intraoperative FiOAnalyses were per intention-to-treat principle. Qualitative and quantitative variables were presented as 